Key Highlights
- Lynch Regenerative Medicine (LRM) completes Series A financing round.
- Series A led by Champion VC and Dr. Samuel Lynch, founder and CEO.
- Introduction of Ariessence™ Pure PDGF+ for skin aesthetics.
- Pure PDGF technology proven in millions of patients globally.
- Plans to expand team across commercialization, business development, and clinical development.
Source: Business Wire
Notable Quote
- “I’ve spent my career studying regenerative medicine and developing and commercializing PDGF products to regenerate tissues lost due to trauma or disease. I’m most excited to bring pure PDGF-based solutions to the skincare market, where we see the largest unmet need for proven solutions for skin rejuvenation and regeneration. Growth factors are playing an important role in skincare today, but there are no other solutions backed by the level of scientific and clinical evidence that supports the safety and effectiveness of pure PDGF. Arriessence Pure PDGF+ builds on this truly unique foundation of success in regenerative medicine.” — Dr. Samuel Lynch, Founder and CEO at LRM
SoHC's Take
Lynch Regenerative Medicine’s successful Series A financing is a significant milestone in the field of regenerative medicine, especially within the rapidly growing skincare market. With a robust foundation of proven pure PDGF technology, LRM is well-positioned to meet the high demand for effective skin rejuvenation solutions. The involvement of Champion VC and the leadership of Dr. Samuel Lynch underscore the credibility and potential of LRM’s innovative approach. The expansion into the aesthetics sector with Ariessence™ Pure PDGF+ promises to set new standards in skin regeneration and rejuvenation, leveraging decades of clinical success and scientific validation. This move is poised to redefine the landscape of aesthetic regenerative medicine, offering safe, effective, and scientifically backed solutions for healthier-looking skin.
